Search

Your search keyword '"Stinco, G"' showing total 427 results
Start Over Author "Stinco, G"
Sorry, I don't understand your search. ×
427 results on '"Stinco, G"'

1. Bimekizumab in Biologics-Refractory Psoriatic Arthritis: A Real-Life Analysis from a Combined Dermatology-Rheumatology Clinic

Author

Zabotti A, Cabas N, Giovannini I, Guella S, Cereser L, Zuiani C, Stinco G, Quartuccio L, and Errichetti E

Subjects
biologics, bimekizumab, psoriatic arthritis, refractory., Dermatology, RL1-803
Abstract

Alen Zabotti,1 Nicola Cabas,1 Ivan Giovannini,1 Silvia Guella,1 Lorenzo Cereser,2 Chiara Zuiani,2 Giuseppe Stinco,3 Luca Quartuccio,1 Enzo Errichetti3 1Department of Medical and Biological Sciences, Rheumatology Institute, Azienda sanitaria universitaria Friuli Centrale, Udine, Italy; 2Department of Medicine, Institute of Radiology, Azienda sanitaria universitaria Friuli Centrale, Udine, Italy; 3Department of Medical and Biological Sciences, Dermatology Institute, Azienda Sanitaria Universitaria Friuli Centrale, Udine, ItalyCorrespondence: Enzo Errichetti, Institute of Dermatology, Department of Medical Area, University of Udine, Piazzale Santa Maria della Misericordia, 15, Udine, 33100, Italy, Tel +39 0432559822, Email enzoerri@yahoo.it

Published
2024

2. Dermoscopy of Primary Localized Cutaneous Nodular Amyloidosis

Author

Pulgarin LM, De Pellegrin A, Stinco G, and Errichetti E

Subjects
amyloidosis, dermoscopy, diagnosis, differential diagnosis., Dermatology, RL1-803
Abstract

Laura Manuela Pulgarin,1 Alessandro De Pellegrin,2 Giuseppe Stinco,3 Enzo Errichetti3 1Department of Dermatology, Universidad del Valle, Cali, Colombia; 2Department of Pathology, Udine “S. Maria della Misericordia” University Hospital, Udine, Italy; 3Institute of Dermatology, Department of Medicine, University of Udine, Udine, ItalyCorrespondence: Enzo Errichetti, Institute of Dermatology, Department of Medical Area, University of Udine, Piazzale Santa Maria della Misericordia, 15, Udine, 33100, Italy, Tel +39 0432559822, Email enzoerri@yahoo.it

Published
2024

3. Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study

Author

Russo F, Galluzzo M, Stingeni L, Persechino S, Zichichi L, Conti A, Giofrè C, Dini V, Vispi M, Atzori L, Cattaneo A, Parodi A, Bardazzi F, Stinco G, Dapavo P, Girolomoni G, Musumeci ML, Papini M, Venturini M, Dastoli S, Di Nuzzo S, Fargnoli MC, Pagnanelli G, Bernardini N, Gambini DM, Malagoli P, Mazzatenta C, Peris K, Zalaudek I, Fabbrocini G, Loconsole F, Vassallo C, Pietroleonardo L, Prignano F, Franchi C, Offidani AM, Bonifati C, Di Lernia V, Gigante G, Bartezaghi MS, Franchi M, Ursoleo P, and Aloisi E

Subjects
psoriasis, secukinumab, real-world evidence, drug survival, supreme, Dermatology, RL1-803
Abstract

Filomena Russo,1 Marco Galluzzo,2,3 Luca Stingeni,4 Severino Persechino,5 Leonardo Zichichi,6 Andrea Conti,7 Claudia Giofrè,8 Valentina Dini,9 Martina Vispi,10 Laura Atzori,11 Angelo Cattaneo,12 Aurora Parodi,13 Federico Bardazzi,14 Giuseppe Stinco,15 Paolo Dapavo,16 Giampiero Girolomoni,17 Maria Letizia Musumeci,18 Manuela Papini,19 Marina Venturini,20 Stefano Dastoli,21 Sergio Di Nuzzo,22 Maria Concetta Fargnoli,23 Gianluca Pagnanelli,24 Nicoletta Bernardini,25 Daniele Mario Gambini,26 Piergiorgio Malagoli,27 Carlo Mazzatenta,28 Ketty Peris,29 Iris Zalaudek,30 Gabriella Fabbrocini31 ,† Francesco Loconsole,32 Camilla Vassallo,33 Lucia Pietroleonardo,34 Francesca Prignano,35 Chiara Franchi,36 Anna Maria Offidani,37 Claudio Bonifati,38 Vito Di Lernia,39 Giovanni Gigante,40 Marta Silvia Bartezaghi,40 Matteo Franchi,41,42 Paola Ursoleo,40 Elisabetta Aloisi40 1Dermatology Section, Department of Medical, Surgical and Neurological Science, University of Siena, S. Maria Alle Scotte Hospital, Siena, Italy; 2Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy; 3Dermatology Unit, Fondazione Policlinico “Tor Vergata”, Rome, Italy; 4Section of Dermatology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy; 5Dermatology Unit, NESMOS Department, Faculty of Medicine & Psychology, Sapienza University of Rome, Sant’Andrea University Hospital, Rome, Italy; 6Unit of Dermatology, San Antonio Abate Hospital, Trapani, Italy; 7Section of Dermatology, Department of Specialized Medicine, University of Modena and Reggio Emilia, Modena, Italy; 8U.O.C. Dermatologia, A.O. Papardo, Messina, Italy; 9Section of Dermatology, Department of Medicine and Oncology, University of Pisa, Pisa, Italy; 10Dermatology Unit, Misericordia Hospital, Grosseto, Italy; 11Dermatology Unit, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy; 12Dermatology Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy; 13Section of Dermatology, DiSSal University of Genoa, Ospedale-Policlinico San Martino IRCCS, Genova, Italy; 14Dermatology Division, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy; 15Section of Dermatology, Department of Medicine, University of Udine, Udine, Italy; 16Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy; 17Section of Dermatology, Department of Medicine, University of Verona, Verona, Italy; 18Section of Dermatology, Department of Medical and Surgical Specialties, University of Catania, Catania, Italy; 19Dermatology Clinic of Terni, University of Perugia, Perugia, Italy; 20Section of Dermatology, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; 21Department of Health Sciences, Magna Graecia University, Catanzaro, Italy; 22Department of Medicine and Surgery, University of Parma, Parma, Italy; 23Section of Dermatology, Department of Biotechnological and Applied Clinical Science, University of L’Aquila, L’Aquila, Italy; 24Department of Dermatology, Istituto Dermopatico dell’Immacolata - IRCCS, Roma, Italy; 25Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Dermatology Unit, “Daniele Innocenzi”, Asl Latina, Italy; 26Dermatology Unit, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy; 27Dermatology Unit, Azienda Ospedaliera San Donato Milanese, Milan, Italy; 28Dermatology Unit, Lucca Azienda USL Toscana Nord Ovest, Pisa, Italy; 29Department of Translational Medicine and Surgery, IRCCS A. Gemelli University Polyclinic Foundation, Sacred Heart Catholic University, Rome, Italy; 30Department of Dermatology, University of Trieste, Trieste, Italy; 31Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; 32Department of Dermatology, University of Bari, Bari, Italy; 33Institute of Dermatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy; 34Dermatology Unit, Vito Fazzi Hospital, Lecce, Italy; 35Dermatology Clinic, Department of Health Sciences, University of Florence, Florence, Italy; 36Dermatology Unit, IRCCS IO Galeazzi, Milan, Italy; 37Dermatological Clinic, Polytechnic University of the Marche Region, Ancona, Italy; 38Department of Dermatology, Istituto Dermatologico San Gallicano - IRCCS, Roma, Italy; 39Dermatology Unit, Arcispedale S. Maria Nuova IRCCS, Reggio Emilia, Italy; 40Novartis Farma SpA, Origgio, Italy; 41National Centre for Healthcare Research and Pharmacoepidemiology, Milan, Italy; 42Laboratory of Healthcare Research and Pharmacoepidemiology, Department of Statistics and Quantitative Methods, University of Milano Bicocca, Milan, Italy†Gabriella Fabbrocini passed away on 3 March 2023Correspondence: Filomena Russo, Dermatology Section, Department of Medical, Surgical and Neurological Science, University of Siena, S. Maria Alle Scotte Hospital, Siena, Italy, Email file.russo@libero.itPurpose: SUPREME, a phase IIIb study conducted in Italy, demonstrated safety and high efficacy of secukinumab for up to 72 weeks in patients with moderate-to-severe plaque-type psoriasis. SUPREME 2.0 study aimed to provide real-world data on the long-term drug survival and effectiveness of secukinumab beyond 72 weeks.Patients and Methods: SUPREME 2.0 is a retrospective observational chart review study conducted in patients previously enrolled in SUPREME study. After the end of the SUPREME study, eligible patients continued treatment as per clinical practice, and their effectiveness and drug survival data were retrieved from medical charts.Results: Of the 415 patients enrolled in the SUPREME study, 297 were included in SUPREME 2.0; of which, 210 (70.7%) continued secukinumab treatment throughout the 42-month observation period. Patients in the biologic-naïve cohort had higher drug survival than those in the biologic-experienced cohort (74.9% vs 61.7%), while HLA-Cw6–positive and HLA-Cw6–negative patients showed similar drug survival (69.3% and 71.9%). After 42 months, Psoriasis Area and Severity Index (PASI) 90 was achieved by 79.6% of patients overall; with a similar proportion of biologic-naïve and biologic-experienced patients achieving PASI90 (79.8% and 79.1%). The mean absolute PASI score reduced from 21.94 to 1.38 in the overall population, 21.90 to 1.24 in biologic-naïve and 22.03 to 1.77 in biologic-experienced patients after 42 months. The decrease in the absolute PASI score was comparable between HLA-Cw6–positive and HLA–Cw6-negative patients. The baseline Dermatology Life Quality Index scores also decreased in the overall patients (10.5 to 2.32) and across all study sub-groups after 42 months. Safety was consistent with the known profile of secukinumab, with no new findings.Conclusion: In this real-world cohort study, secukinumab showed consistently high long-term drug survival and effectiveness with a favourable safety profile.Keywords: psoriasis, secukinumab, real-world evidence, drug survival, SUPREME

Published
2023

4. Therapeutic management of classic lichen planopilaris: a systematic review

Author

Errichetti E, Figini M, Croatto M, and Stinco G

Subjects
Lichen planopilaris, management, therapy, treatment., Dermatology, RL1-803
Abstract

Enzo Errichetti, Matteo Figini, Margherita Croatto, Giuseppe Stinco Department of Experimental and Clinical Medicine, Institute of Dermatology, University of Udine, Udine, Italy Abstract: Several treatment strategies have been proposed in classic lichen planopilaris (LPP), although no gold standard therapeutic approach has been recognized so far due to the variable and, sometimes, contradictory results reported in the literature, as well as due to the lack of guidelines and randomized controlled trials. In the present review, we sought to provide an updated overview on the treatment of classic LPP by analyzing the level of evidence of published studies, also proposing a possible therapeutic strategy according to the findings highlighted in this systematic review. Keywords: lichen planopilaris, management, therapy, treatment

Published
2018

5. COVID 19-associated chilblain-like acral lesions among children and adolescents: an Italian retrospective, multicenter study

Author

Romita, P., Maronese, C. A., de Marco, A., Balestri, R., Belloni Fortina, A., Brazzelli, V., Colonn, C., Di Lernia, V., El Hachem, May, Fabbrocini, G., Foti, C., Frasin, L. A., Guarneri, C., Guerriero, Cristina, Guida, S., Locatelli, A., Neri, Ilaria, Occella, C., Offidani, A., Oranges, T., Pellacani, G., Stinco, G., Stingeni, L., Barbagallo, T., Campanati, A., Cannavo, S. P., Caroppo, F., Cavalli, R., Costantini, Alessio, Cucchia, R., Diociaiuti, Andrea, Filippeschi, C., Francomano, M., Giancristoforo, S., Giuffrida, R., Martina, E., Monzani, N. A., Nappa, P., Pastorino, C., Patrizi, A., Peccerillo, F., Peris, Ketty, Recalcati, S., Rizzoli, L., Simonetti, O., Vastarella, M., Virdi, A., Marzano, A. V., Bonamonte, D., El Hachem M., Guerriero C., Neri I., Costantini A., Diociaiuti A., Peris K. (ORCID:0000-0002-5237-0463), Romita, P., Maronese, C. A., de Marco, A., Balestri, R., Belloni Fortina, A., Brazzelli, V., Colonn, C., Di Lernia, V., El Hachem, May, Fabbrocini, G., Foti, C., Frasin, L. A., Guarneri, C., Guerriero, Cristina, Guida, S., Locatelli, A., Neri, Ilaria, Occella, C., Offidani, A., Oranges, T., Pellacani, G., Stinco, G., Stingeni, L., Barbagallo, T., Campanati, A., Cannavo, S. P., Caroppo, F., Cavalli, R., Costantini, Alessio, Cucchia, R., Diociaiuti, Andrea, Filippeschi, C., Francomano, M., Giancristoforo, S., Giuffrida, R., Martina, E., Monzani, N. A., Nappa, P., Pastorino, C., Patrizi, A., Peccerillo, F., Peris, Ketty, Recalcati, S., Rizzoli, L., Simonetti, O., Vastarella, M., Virdi, A., Marzano, A. V., Bonamonte, D., El Hachem M., Guerriero C., Neri I., Costantini A., Diociaiuti A., and Peris K. (ORCID:0000-0002-5237-0463)

Abstract

BACKGROUND: Since the COVID-19 pandemic started, great interest has been given to this disease, especially to its possible clinical presentations. Besides classical respiratory symptoms, dermatological manifestations occur quite often among infected and non-infected patients, particularly in children. A prominent IFN-I response, that is generally higher in children compared to adults, may not only cause chilblain lesions, but it could also prevent infection and viral replication, thus justifying the negative swab results, as well as the absence of relevant systemic symptoms in positive cases. Indeed, reports have emerged describing chilblain-like acral lesions in children and adolescents with either proven or suspected infection. METHODS: Patients aged from 1 to 18 years old were enrolled in this study from 23 Italian dermatological units and were observed for an overall period of 6 months. Clinical pictures were collected along with data on the location and duration of skin lesions, their association with concomitant local and systemic symptoms, presence of nail and/or mucosal involvement, as well as histological, laboratory and imaging findings. RESULTS: One hundred thirty-seven patients were included, of whom 56.9% were females. Mean age was 11.97±3.66 years. The most commonly affected sites were the feet (77 patients, 56.2%). Lesions (48.5%) featured cyanosis, chilblains, blisters, ecchymosis, bullae, erythema, edema, and papules. Concomitant skin manifestations included maculo-papular rashes (30%), unspecified rashes (25%), vesicular rashes (20%), erythema multiforme (10%), urticaria (10%) and erythema with desquamation (5%). Forty-one patients (29.9%) reported pruritus as the main symptom associated with chilblains, and 56 out of 137 patients also reported systemic symptoms such as respiratory symptoms (33.9%), fever (28%), intestinal (27%), headache (5.5%), asthenia (3.5%), and joint pain (2%). Associated comorbid conditions were observed in 9 patients presen

Published
2023

6. Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study

Author

Russo, F, Galluzzo, M, Stingeni, L, Persechino, S, Zichichi, L, Conti, A, Giofrè, C, Dini, V, Vispi, M, Atzori, L, Cattaneo, A, Parodi, A, Bardazzi, F, Stinco, G, Dapavo, P, Girolomoni, G, Musumeci, M, Papini, M, Venturini, M, Dastoli, S, Di Nuzzo, S, Fargnoli, M, Pagnanelli, G, Bernardini, N, Gambini, D, Malagoli, P, Mazzatenta, C, Peris, K, Zalaudek, I, Fabbrocini, G, Loconsole, F, Vassallo, C, Pietroleonardo, L, Prignano, F, Franchi, C, Offidani, A, Bonifati, C, Di Lernia, V, Gigante, G, Bartezaghi, M, Franchi, M, Ursoleo, P, Aloisi, E, Russo, Filomena, Galluzzo, Marco, Stingeni, Luca, Persechino, Severino, Zichichi, Leonardo, Conti, Andrea, Giofrè, Claudia, Dini, Valentina, Vispi, Martina, Atzori, Laura, Cattaneo, Angelo, Parodi, Aurora, Bardazzi, Federico, Stinco, Giuseppe, Dapavo, Paolo, Girolomoni, Giampiero, Musumeci, Maria Letizia, Papini, Manuela, Venturini, Marina, Dastoli, Stefano, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Pagnanelli, Gianluca, Bernardini, Nicoletta, Gambini, Daniele, Malagoli, Piergiorgio, Mazzatenta, Carlo, Peris, Ketty, Zalaudek, Iris, Fabbrocini, Gabriella, Loconsole, Francesco, Vassallo, Camilla, Pietroleonardo, Lucia, Prignano, Francesca, Franchi, Chiara, Offidani, Anna Maria, Bonifati, Claudio, Di Lernia, Vito, Gigante, Giovanni, Bartezaghi, Marta, Franchi, Matteo, Ursoleo, Paola, Aloisi, Elisabetta, Russo, F, Galluzzo, M, Stingeni, L, Persechino, S, Zichichi, L, Conti, A, Giofrè, C, Dini, V, Vispi, M, Atzori, L, Cattaneo, A, Parodi, A, Bardazzi, F, Stinco, G, Dapavo, P, Girolomoni, G, Musumeci, M, Papini, M, Venturini, M, Dastoli, S, Di Nuzzo, S, Fargnoli, M, Pagnanelli, G, Bernardini, N, Gambini, D, Malagoli, P, Mazzatenta, C, Peris, K, Zalaudek, I, Fabbrocini, G, Loconsole, F, Vassallo, C, Pietroleonardo, L, Prignano, F, Franchi, C, Offidani, A, Bonifati, C, Di Lernia, V, Gigante, G, Bartezaghi, M, Franchi, M, Ursoleo, P, Aloisi, E, Russo, Filomena, Galluzzo, Marco, Stingeni, Luca, Persechino, Severino, Zichichi, Leonardo, Conti, Andrea, Giofrè, Claudia, Dini, Valentina, Vispi, Martina, Atzori, Laura, Cattaneo, Angelo, Parodi, Aurora, Bardazzi, Federico, Stinco, Giuseppe, Dapavo, Paolo, Girolomoni, Giampiero, Musumeci, Maria Letizia, Papini, Manuela, Venturini, Marina, Dastoli, Stefano, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Pagnanelli, Gianluca, Bernardini, Nicoletta, Gambini, Daniele, Malagoli, Piergiorgio, Mazzatenta, Carlo, Peris, Ketty, Zalaudek, Iris, Fabbrocini, Gabriella, Loconsole, Francesco, Vassallo, Camilla, Pietroleonardo, Lucia, Prignano, Francesca, Franchi, Chiara, Offidani, Anna Maria, Bonifati, Claudio, Di Lernia, Vito, Gigante, Giovanni, Bartezaghi, Marta, Franchi, Matteo, Ursoleo, Paola, and Aloisi, Elisabetta

Abstract

Purpose: SUPREME, a phase IIIb study conducted in Italy, demonstrated safety and high efficacy of secukinumab for up to 72 weeks in patients with moderate-to-severe plaque-type psoriasis. SUPREME 2.0 study aimed to provide real-world data on the long-term drug survival and effectiveness of secukinumab beyond 72 weeks. Patients and Methods: SUPREME 2.0 is a retrospective observational chart review study conducted in patients previously enrolled in SUPREME study. After the end of the SUPREME study, eligible patients continued treatment as per clinical practice, and their effectiveness and drug survival data were retrieved from medical charts. Results: Of the 415 patients enrolled in the SUPREME study, 297 were included in SUPREME 2.0; of which, 210 (70.7%) continued secukinumab treatment throughout the 42-month observation period. Patients in the biologic-naïve cohort had higher drug survival than those in the biologic-experienced cohort (74.9% vs 61.7%), while HLA-Cw6–positive and HLA-Cw6–negative patients showed similar drug survival (69.3% and 71.9%). After 42 months, Psoriasis Area and Severity Index (PASI) 90 was achieved by 79.6% of patients overall; with a similar proportion of biologic-naïve and biologic-experienced patients achieving PASI90 (79.8% and 79.1%). The mean absolute PASI score reduced from 21.94 to 1.38 in the overall population, 21.90 to 1.24 in biologic-naïve and 22.03 to 1.77 in biologic-experienced patients after 42 months. The decrease in the absolute PASI score was comparable between HLA-Cw6–positive and HLA–Cw6-negative patients. The baseline Dermatology Life Quality Index scores also decreased in the overall patients (10.5 to 2.32) and across all study sub-groups after 42 months. Safety was consistent with the known profile of secukinumab, with no new findings. Conclusion: In this real-world cohort study, secukinumab showed consistently high long-term drug survival and effectiveness with a favourable safety profile.

Published
2023

7. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis

Author

Fargnoli, M. C., Esposito, M., Ferrucci, S., Girolomoni, G., Offidani, A., Patrizi, A., Peris, K., Costanzo, A., Malara, G., Pellacani, G., Romanelli, M., Amerio, P., Cristaudo, A., Flori, M. L., Motolese, A., Betto, P., Patruno, C., Pigatto, P., Sirna, R., Stinco, G., Zalaudek, I., Bianchi, L., Boccaletti, V., Cannavo, S. P., Cusano, F., Lembo, S., Mozzillo, R., Gallo, R., Potenza, C., Rongioletti, F., Tiberio, R., Grieco, T., Micali, G., Persechino, S., Pettinato, M., Pucci, S., Savi, E., Stingeni, L., Romano, A., Argenziano, G., Hansel, K., Fargnoli, M. C., Esposito, M., Ferrucci, S., Girolomoni, G., Offidani, A., Patrizi, A., Peris, K., Costanzo, A., Malara, G., Pellacani, G., Romanelli, M., Amerio, P., Cristaudo, A., Flori, M. L., Motolese, A., Betto, P., Patruno, C., Pigatto, P., Sirna, R., Stinco, G., Zalaudek, I., Bianchi, L., Boccaletti, V., Cannavo, S. P., Cusano, F., Lembo, S., Mozzillo, R., Gallo, R., Potenza, C., Rongioletti, F., Tiberio, R., Grieco, T., Micali, G., Persechino, S., Pettinato, M., Pucci, S., Savi, E., Stingeni, L., Romano, A., Argenziano, G., Fargnoli, Mc, Esposito, M, Ferrucci, S, Girolomoni, G, Offidani, A, Patrizi, A, Peris, K, Costanzo, A, Malara, G, Pellacani, G, Romanelli, M, Amerio, P, Cristaudo, A, Flori, Ml, Motolese, A, Betto, P, Patruno, C, Pigatto, P, Sirna, R, Stinco, G, Zalaudek, I, Bianchi, L, Boccaletti, V, Cannavò, Sp, Cusano, F, Lembo, S, Mozzillo, R, Gallo, R, Potenza, C, Rongioletti, F, Tiberio, R, Grieco, T, Micali, G, Persechino, S, Pettinato, M, Pucci, S, Savi, E, Stingeni, L, Romano, A, Argenziano, G, and Dupilumab Italian National Access Program (Dup-INAP, group).

Subjects
Male, Dermatitis, Severity of Illness Index, Cohort Studies, 030207 dermatology & venereal diseases, 0302 clinical medicine, Quality of life, Monoclonal, 80 and over, Humanized, Aged, 80 and over, Real-life, Atopic dermatitis, Middle Aged, Atopic dermatiti, Dupilumab, humanities, Treatment Outcome, atopic dermatitis, dupilumab, real-life, Female, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Cohort study, atopic dermatiti, Adult, medicine.medical_specialty, Context (language use), Dermatology, Antibodies, Monoclonal, Humanized, Antibodies, Atopic, Dermatitis, Atopic, 03 medical and health sciences, Young Adult, Internal medicine, Severity of illness, medicine, Humans, Adverse effect, Aged, Retrospective Studies, 030203 arthritis & rheumatology, business.industry, Pruritus, Retrospective cohort study, medicine.disease, Quality of Life, business, Sleep
Abstract

Background: Dupilumab, a fully human monoclonal antibody targeting the alpha subunit of IL-4 was recently approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients. Objective: To assess dupilumab effectiveness and safety in adults with moderate-to-severe AD in a real-life Italian multicentre retrospective cohort. Methods: Adult moderate-to-severe AD patients, referring to 39 Italian centers, received dupilumab in the context of a national patient access program. Disease assessment was performed at baseline, after 4 and 16 weeks of treatment using Eczema-Area-and-Severity-Index (EASI) score, itch and sleep numerical-rating-score (itch-NRS, sleep-NRS) and Dermatology-Life-Quality-Index (DLQI). Results: A total of 109 (71 M/38F) patients was studied. There was a significant reduction in EASI score, itch-NRS, sleep-NRS and DLQI from baseline to week 4 and a further significant decline to week 16. EASI 50, EASI75 and EASI90 were achieved by 59.6%, 28.4% and 9.3% of patients at 4 weeks and by 87.2%, 60.6% and 32.4% of them at 16 weeks, respectively. Adverse events were experienced by 19.2% (21/109) of the patients and they were all mild in intensity, being conjunctivitis the most common side effect. Conclusions: Dupilumab significantly improved disease severity, pruritus, sleep loss and quality of life with an acceptable safety profile.

Published
2021

9. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis

Author

Gisondi, P., Fargnoli, M. C., Amerio, P., Argenziano, G., Bardazzi, F., Bianchi, L., Chiricozzi, Andrea, Conti, A., Corazza, M., Costanzo, A., Dapavo, P., De Simone, Clara, Fabbrocini, G., Feliciani, C., Foti, C., Girolomoni, G., Guarneri, C., Marzano, A. V., Micali, G., Offidani, A., Parodi, A., Pellacani, G., Piaserico, S., Prignano, F., Romanelli, M., Rongioletti, F., Rubegni, P., Stinco, G., Stingeni, L., Tomasini, C. F., Venturini, M., Peris, Ketty, Calzavara-Pinton, P., Chiricozzi A. (ORCID:0000-0002-6739-0387), DE Simone C. (ORCID:0000-0002-0898-0045), Peris K. (ORCID:0000-0002-5237-0463), Gisondi, P., Fargnoli, M. C., Amerio, P., Argenziano, G., Bardazzi, F., Bianchi, L., Chiricozzi, Andrea, Conti, A., Corazza, M., Costanzo, A., Dapavo, P., De Simone, Clara, Fabbrocini, G., Feliciani, C., Foti, C., Girolomoni, G., Guarneri, C., Marzano, A. V., Micali, G., Offidani, A., Parodi, A., Pellacani, G., Piaserico, S., Prignano, F., Romanelli, M., Rongioletti, F., Rubegni, P., Stinco, G., Stingeni, L., Tomasini, C. F., Venturini, M., Peris, Ketty, Calzavara-Pinton, P., Chiricozzi A. (ORCID:0000-0002-6739-0387), DE Simone C. (ORCID:0000-0002-0898-0045), and Peris K. (ORCID:0000-0002-5237-0463)

Abstract

SIDeMaST (Società Italiana di Dermatologia Medica, Chirurgica, Estetica e delle Malattie Sessualmente Trasmesse) contributed to the development of the present guideline on the systemic treatment of chronic plaque psoriasis. With the permission of EuroGuiDerm, SIDeMaST adapted the guideline to the Italian healthcare context to supply a reliable and affordable tool to Italian physicians who take care of patients affected by moderate to severe plaque psoriasis. The content of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline, suggestions for disease severity grading and treatment goals. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs including acitretin, cyclosporine, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab. Moreover, the guideline provides guidance for specific clinical situations such as patient with concomitant psoriatic arthritis, inflammatory bowel disease, a history of malignancies, a history of depression, diabetes, viral hepatitis, disease affecting the heart or the kidneys as well as concomitant neurological disease. Advice on how to screen for tuberculosis and recommendations on how to manage patients with a positive tuberculosis test result are given. It further covers treatment for pregnant women or those with childbearing potential. Information on vaccination, immunogenicity and systemic treatment during the COVID-19 pandemic is also provided.

Published
2022

10. Dermoscopic spectrum of mycosis fungoides: a retrospective observational study by the International Dermoscopy Society

Author

Errichetti, E., primary, Apalla, Z., additional, Geller, S., additional, Sławińska, M., additional, Kyrgidis, A., additional, Kaminska‐Winciorek, G., additional, Jurakic Toncic, R., additional, Bobos, M., additional, Rados, J., additional, Ledic Drvar, D., additional, Ceovic, R., additional, Akay, B. N., additional, Piccolo, V., additional, Myskowski, P., additional, Vitiello, P., additional, Russo, T., additional, Argenziano, G., additional, Sokołowska‐Wojdyło, M., additional, Sobjanek, M., additional, Stojkovic‐Filipovic, J., additional, Longo, C., additional, Pellacani, G., additional, Stinco, G., additional, and Lallas, A., additional

Published
2022
Full Text
View/download PDF

17. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study

Author

Patruno C., Napolitano M., Argenziano G., Peris K., Ortoncelli M., Girolomoni G., Offidani A., Ferrucci S. M., Amoruso G. F., Rossi M., Stingeni L., Malara G., Grieco T., Foti C., Gattoni M., Loi C., Iannone M., Talamonti M., Stinco G., Rongioletti F., Pigatto P. D., Cristaudo A., Nettis E., Corazza M., Guarneri F., Amerio P., Esposito M., Belloni Fortina A., Potenza C., Fabbrocini G., Angileri L., Bianchelli T., Borghi A., Buligan C., Calabrese G., Calzavara Pinton P., Caroppo F., Chello C., Dal Bello G., Damiani G., Fargnoli M. C., Ferrillo M., Galluzzo M., Gori N., Gualdi G., Hansel K., Macchia L., Mariano M., Nistico S. P., Pertusi G., Piras V., Provenzano E., Ravaioli G. M., Ribero S., Romanelli M., Romita P., Tolino E., Trifiro C., Patruno, C., Napolitano, M., Argenziano, G., Peris, K., Ortoncelli, M., Girolomoni, G., Offidani, A., Ferrucci, S. M., Amoruso, G. F., Rossi, M., Stingeni, L., Malara, G., Grieco, T., Foti, C., Gattoni, M., Loi, C., Iannone, M., Talamonti, M., Stinco, G., Rongioletti, F., Pigatto, P. D., Cristaudo, A., Nettis, E., Corazza, M., Guarneri, F., Amerio, P., Esposito, M., Belloni Fortina, A., Potenza, C., Fabbrocini, G., Angileri, L., Bianchelli, T., Borghi, A., Buligan, C., Calabrese, G., Calzavara Pinton, P., Caroppo, F., Chello, C., Dal Bello, G., Damiani, G., Fargnoli, M. C., Ferrillo, M., Galluzzo, M., Gori, N., Gualdi, G., Hansel, K., Macchia, L., Mariano, M., Nistico, S. P., Pertusi, G., Piras, V., Provenzano, E., Ravaioli, G. M., Ribero, S., Romanelli, M., Romita, P., Tolino, E., and Trifiro, C.

Subjects
Adult, medicine.medical_specialty, Adolescent, multicentre, Treatment outcome, Eczema, Socio-culturale, Dermatitis, Dupilumab, atopic dermatitis, multicentre, real-life study, Dermatology, Antibodies, Monoclonal, Humanized, elderly, Severity of Illness Index, Antibodies, Atopic, Dermatitis, Atopic, 030207 dermatology & venereal diseases, 03 medical and health sciences, Young Adult, Settore MED/35, 0302 clinical medicine, Internal medicine, Aged, Humans, Middle Aged, Retrospective Studies, Monoclonal, Medicine, 030212 general & internal medicine, Adverse effect, Humanized, atopic dermatitis, business.industry, dupilumab, Atopic dermatitis, medicine.disease, humanities, Safety profile, Infectious Diseases, Observational study, real-life study, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Life study, business, Prurigo nodularis
Abstract

Background: Treatment of moderate-to-severe atopic dermatitis (AD) in the elderly may be challenging, due to side-effects of traditional anti-inflammatory drugs and to comorbidities often found in this age group. Furthermore, efficacy and safety of innovative drugs such as dupilumab are not yet well known. Objectives: A multicentre retrospective, observational, real-life study on the efficacy and safety of dupilumab was conducted in a group of patients aged ≥65years and affected by severe AD. Their main clinical features were also examined. Methods: Data of elderly patients with severe (EASI ≥24) AD treated with dupilumab at label dosage for 16weeks were retrospectively collected. Treatment outcome was assessed by comparing objective (EASI) and subjective (P-NRS, S-NRS and DLQI) scores at baseline and after 16weeks of treatment. Results: Two hundred and seventy-six patients were enrolled in the study. They represented 11.37% of all patients with severe AD. Flexural eczema was the most frequent clinical phenotype, followed by prurigo nodularis. The coexistence of more than one phenotype was found in 63/276 (22.82%) subjects. Data on the 16-week treatment with dupilumab were available for 253 (91.67%) patients. Efficacy of dupilumab was demonstrated by a significant reduction of all the scores. No statistically significant difference regarding efficacy was found in elderly patients when compared to the group of our AD patients aged 18–64years, treated with dupilumab over the same period. Furthermore, only 18 (6.52%) patients discontinued the drug due to inefficacy. Sixty-one (22.51%) patients reported adverse events, conjunctivitis and flushing being the most frequent. One (0.36%) patient only discontinued dupilumab due to an adverse event. Conclusions: Therapy with dupilumab led to a significant improvement of AD over a 16-week treatment period, with a good safety profile. Therefore, dupilumab could be considered as an efficacious and safe treatment for AD also in the elderly.

Published
2020

18. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis

Author

Fargnoli, Maria Concetta, Esposito, M., Ferrucci, S., Girolomoni, G., Offidani, A., Patrizi, A., Peris, Ketty, Costanzo, Rosa Maria Alba, Malara, G., Pellacani, G., Romanelli, Margherita, Amerio, P., Cristaudo, A., Flori, M. L., Motolese, A., Betto, P., Patruno, C., Pigatto, P., Sirna, R., Stinco, G., Zalaudek, Iri, Bianchi, L., Boccaletti, V., Cannavo, S. P., Cusano, F., Lembo, S., Mozzillo, R., Gallo, Rosanna, Potenza, C., Rongioletti, F., Tiberio, R., Grieco, T., Micali, G., Persechino, S., Pettinato, M., Pucci, S., Savi, E., Stingeni, L., Romano, A., Argenziano, G., Fargnoli M. C., Peris K. (ORCID:0000-0002-5237-0463), Costanzo A., Romanelli M., Zalaudek I., Gallo R., Fargnoli, Maria Concetta, Esposito, M., Ferrucci, S., Girolomoni, G., Offidani, A., Patrizi, A., Peris, Ketty, Costanzo, Rosa Maria Alba, Malara, G., Pellacani, G., Romanelli, Margherita, Amerio, P., Cristaudo, A., Flori, M. L., Motolese, A., Betto, P., Patruno, C., Pigatto, P., Sirna, R., Stinco, G., Zalaudek, Iri, Bianchi, L., Boccaletti, V., Cannavo, S. P., Cusano, F., Lembo, S., Mozzillo, R., Gallo, Rosanna, Potenza, C., Rongioletti, F., Tiberio, R., Grieco, T., Micali, G., Persechino, S., Pettinato, M., Pucci, S., Savi, E., Stingeni, L., Romano, A., Argenziano, G., Fargnoli M. C., Peris K. (ORCID:0000-0002-5237-0463), Costanzo A., Romanelli M., Zalaudek I., and Gallo R.

Abstract

Background: Dupilumab, a fully human monoclonal antibody targeting the alpha subunit of IL-4 was recently approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients. Objective: To assess dupilumab effectiveness and safety in adults with moderate-to-severe AD in a real-life Italian multicentre retrospective cohort. Methods: Adult moderate-to-severe AD patients, referring to 39 Italian centers, received dupilumab in the context of a national patient access program. Disease assessment was performed at baseline, after 4 and 16 weeks of treatment using Eczema-Area-and-Severity-Index (EASI) score, itch and sleep numerical-rating-score (itch-NRS, sleep-NRS) and Dermatology-Life-Quality-Index (DLQI). Results: A total of 109 (71 M/38F) patients was studied. There was a significant reduction in EASI score, itch-NRS, sleep-NRS and DLQI from baseline to week 4 and a further significant decline to week 16. EASI 50, EASI75 and EASI90 were achieved by 59.6%, 28.4% and 9.3% of patients at 4 weeks and by 87.2%, 60.6% and 32.4% of them at 16 weeks, respectively. Adverse events were experienced by 19.2% (21/109) of the patients and they were all mild in intensity, being conjunctivitis the most common side effect. Conclusions: Dupilumab significantly improved disease severity, pruritus, sleep loss and quality of life with an acceptable safety profile.

Published
2021

20. Cutaneous adverse reactions after m‐RNA COVID‐19 vaccine: early reports from Northeast Italy

Author

Farinazzo, E., primary, Ponis, G., additional, Zelin, E., additional, Errichetti, E., additional, Stinco, G., additional, Pinzani, C., additional, Gambelli, A., additional, De Manzini, N., additional, Toffoli, L., additional, Moret, A., additional, Agozzino, M., additional, Conforti, C., additional, Di Meo, N., additional, Schincariol, P., additional, and Zalaudek, I., additional

Published
2021
Full Text
View/download PDF

21. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis. results from extension phase of the SUPREME study

Author

Papini, M, Cusano, F, Romanelli, M, Burlando, M, Stinco, G, Girolomoni, G, Peris, K, Potenza, C, Offidani, A, Bartezaghi, M, Aloisi, E, Costanzo A, Bianchi L, Bottoni U, Buligan C, Brazzelli V, Campanati A, Cantoresi F, Capo A, Cattaneo A, Dapavo P, Del Giglio M, Di Lernia V, Di Nuzzo S, De Simone C, Dusi D, Fargnoli MC, Flori ML, Franchi C, Galluzzo M, Ghilardi A, Hansel K, Loconsole F, Lora V, Malagoli P, Malara G, Mastrandrea V, Megna M, Mercuri SR, Musumeci ML, Naldi L, Narcisi A, Orsini D, Pagnanelli G, Patrizi A, Pau M, Pellacani G, Persechino S, Piaserico S, Pietroleonardo L, Prignano F, Reseghetti A, Russo F, Sirna R, Skroza N, Stingeni L, Trevisini S, Zane C, Zichichi L, Zini A., Papini, M, Cusano, F, Romanelli, M, Burlando, M, Stinco, G, Girolomoni, G, Peris, K, Potenza, C, Offidani, A, Bartezaghi, M, Aloisi, E, Costanzo, A, Bianchi, L, Bottoni, U, Buligan, C, Brazzelli, V, Campanati, A, Cantoresi, F, Capo, A, Cattaneo, A, Dapavo, P, Del Giglio, M, Di Lernia, V, Di Nuzzo, S, De Simone, C, Dusi, D, Fargnoli, Mc, Flori, Ml, Franchi, C, Galluzzo, M, Ghilardi, A, Hansel, K, Loconsole, F, Lora, V, Malagoli, P, Malara, G, Mastrandrea, V, Megna, M, Mercuri, Sr, Musumeci, Ml, Naldi, L, Narcisi, A, Orsini, D, Pagnanelli, G, Patrizi, A, Pau, M, Pellacani, G, Persechino, S, Piaserico, S, Pietroleonardo, L, Prignano, F, Reseghetti, A, Russo, F, Sirna, R, Skroza, N, Stingeni, L, Trevisini, S, Zane, C, Zichichi, L, and Zini, A.

Subjects
Moderate to severe, medicine.medical_specialty, business.industry, secukinumab, HLA-Cw6, Dermatology, Plaque type psoriasis, moderate-to-severe plaque-type psoriasis, Clinical trial, Severity of illness, Monoclonal, Medicine, In patient, Secukinumab, Settore MED/35 - MALATTIE CUTANEE E VENEREE, business, Prospective cohort study
Abstract

Recent studies have shown that biological drugs approved for treating psoriasis and psoriatic arthritis are not effective in all patients, and that variations in the genome have been associated with different clinical responses or side effects. HLA-Cw6 gene is associated with more severe and early-onset psoriasis. Recent reports have shown that HLA-Cw6 status predicts efficacy of some biologic treatments in psoriasis patients. The Phase 3b SUPREME study (NCT02394561) demonstrated the efficacy of secukinumab in patients with moderate-to-severe plaque-type psoriasis, irrespective of HLA-Cw6 status at week 24. This article is protected by copyright. All rights reserved.

Published
2019

22. Standardization of dermoscopic terminology and basic dermoscopic parameters to evaluate in general dermatology (non‐neoplastic dermatoses): an expert consensus on behalf of the International Dermoscopy Society

Author

Errichetti, E, Zalaudek, I, Kittler, H, Apalla, Z, Argenziano, G, Bakos, R, Blum, A, Braun, R P, Ioannides, D, Lacarrubba, F, Lazaridou, E, Longo, C, Micali, G, Moscarella, E, Paoli, J, Papageorgiou, C, Russo, T, Scope, A, Stinco, G, Thomas, L, Toncic, R J, Tschandl, P, Cabo, H, Hallpern, A, Hofmann‐Wellenhof, R, Malvehy, J, Marghoob, A, Menzies, S, Pellacani, G, Puig, S, et al, University of Zurich, and Errichetti, E

Subjects
2708 Dermatology, 10177 Dermatology Clinic, 610 Medicine & health, Dermatology
Published
2020

23. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study

Author

Patruno, C., Napolitano, M., Argenziano, G., Peris, Ketty, Ortoncelli, M., Girolomoni, G., Offidani, A., Ferrucci, S. M., Amoruso, G. F., Rossi, M., Stingeni, L., Malara, G., Grieco, T., Foti, C., Gattoni, M., Loi, C., Iannone, Maria Teresa, Talamonti, M., Stinco, G., Rongioletti, F., Pigatto, P. D., Cristaudo, A., Nettis, E., Corazza, M., Guarneri, F., Amerio, P., Esposito, M., Belloni Fortina, A., Potenza, C., Fabbrocini, G., Angileri, L., Bianchelli, T., Borghi, A., Buligan, C., Calabrese, G., Calzavara Pinton, P., Caroppo, F., Chello, C., Dal Bello, G., Damiani, G., Fargnoli, Maria Concetta, Ferrillo, M., Galluzzo, M., Gori, Niccolo', Gualdi, G., Hansel, K., Macchia, L., Mariano, M., Nistico, S. P., Pertusi, G., Piras, V., Provenzano, Katia Elisabetta, Ravaioli, G. M., Ribero, S., Romanelli, Margherita, Romita, P., Tolino, E., Trifiro, C., Peris K. (ORCID:0000-0002-5237-0463), Iannone M., Fargnoli M. C., Gori N., Provenzano E., Romanelli M., Patruno, C., Napolitano, M., Argenziano, G., Peris, Ketty, Ortoncelli, M., Girolomoni, G., Offidani, A., Ferrucci, S. M., Amoruso, G. F., Rossi, M., Stingeni, L., Malara, G., Grieco, T., Foti, C., Gattoni, M., Loi, C., Iannone, Maria Teresa, Talamonti, M., Stinco, G., Rongioletti, F., Pigatto, P. D., Cristaudo, A., Nettis, E., Corazza, M., Guarneri, F., Amerio, P., Esposito, M., Belloni Fortina, A., Potenza, C., Fabbrocini, G., Angileri, L., Bianchelli, T., Borghi, A., Buligan, C., Calabrese, G., Calzavara Pinton, P., Caroppo, F., Chello, C., Dal Bello, G., Damiani, G., Fargnoli, Maria Concetta, Ferrillo, M., Galluzzo, M., Gori, Niccolo', Gualdi, G., Hansel, K., Macchia, L., Mariano, M., Nistico, S. P., Pertusi, G., Piras, V., Provenzano, Katia Elisabetta, Ravaioli, G. M., Ribero, S., Romanelli, Margherita, Romita, P., Tolino, E., Trifiro, C., Peris K. (ORCID:0000-0002-5237-0463), Iannone M., Fargnoli M. C., Gori N., Provenzano E., and Romanelli M.

Abstract

Background: Treatment of moderate-to-severe atopic dermatitis (AD) in the elderly may be challenging, due to side-effects of traditional anti-inflammatory drugs and to comorbidities often found in this age group. Furthermore, efficacy and safety of innovative drugs such as dupilumab are not yet well known. Objectives: A multicentre retrospective, observational, real-life study on the efficacy and safety of dupilumab was conducted in a group of patients aged ≥65 years and affected by severe AD. Their main clinical features were also examined. Methods: Data of elderly patients with severe (EASI ≥24) AD treated with dupilumab at label dosage for 16 weeks were retrospectively collected. Treatment outcome was assessed by comparing objective (EASI) and subjective (P-NRS, S-NRS and DLQI) scores at baseline and after 16 weeks of treatment. Results: Two hundred and seventy-six patients were enrolled in the study. They represented 11.37% of all patients with severe AD. Flexural eczema was the most frequent clinical phenotype, followed by prurigo nodularis. The coexistence of more than one phenotype was found in 63/276 (22.82%) subjects. Data on the 16-week treatment with dupilumab were available for 253 (91.67%) patients. Efficacy of dupilumab was demonstrated by a significant reduction of all the scores. No statistically significant difference regarding efficacy was found in elderly patients when compared to the group of our AD patients aged 18–64 years, treated with dupilumab over the same period. Furthermore, only 18 (6.52%) patients discontinued the drug due to inefficacy. Sixty-one (22.51%) patients reported adverse events, conjunctivitis and flushing being the most frequent. One (0.36%) patient only discontinued dupilumab due to an adverse event. Conclusions: Therapy with dupilumab led to a significant improvement of AD over a 16-week treatment period, with a good safety profile. Therefore, dupilumab could be considered as an efficacious and safe tre

Published
2020

24. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis

Author

Fargnoli, Maria Concetta, Esposito, M., Ferrucci, S., Girolomoni, G., Offidani, A., Patrizi, A., Peris, Ketty, Costanzo, Rosa Maria Alba, Malara, G., Pellacani, G., Romanelli, Margherita, Amerio, P., Cristaudo, A., Flori, M. L., Motolese, A., Betto, P., Patruno, C., Pigatto, P., Peccianti, C., Stinco, G., Zalaudek, Iri, Bianchi, L., Boccaletti, V., Cannavo, S. P., Cusano, F., Lembo, S., Mozzillo, R., Gallo, Rosanna, Potenza, C., Rongioletti, F., Tiberio, R., Grieco, T., Micali, G., Persechino, S., Pettinato, M., Pucci, S., Stingeni, L., Caruso, C., Argenziano, G., Fargnoli M. C., Peris K. (ORCID:0000-0002-5237-0463), Costanzo A., Romanelli M., Zalaudek I., Gallo R., Fargnoli, Maria Concetta, Esposito, M., Ferrucci, S., Girolomoni, G., Offidani, A., Patrizi, A., Peris, Ketty, Costanzo, Rosa Maria Alba, Malara, G., Pellacani, G., Romanelli, Margherita, Amerio, P., Cristaudo, A., Flori, M. L., Motolese, A., Betto, P., Patruno, C., Pigatto, P., Peccianti, C., Stinco, G., Zalaudek, Iri, Bianchi, L., Boccaletti, V., Cannavo, S. P., Cusano, F., Lembo, S., Mozzillo, R., Gallo, Rosanna, Potenza, C., Rongioletti, F., Tiberio, R., Grieco, T., Micali, G., Persechino, S., Pettinato, M., Pucci, S., Stingeni, L., Caruso, C., Argenziano, G., Fargnoli M. C., Peris K. (ORCID:0000-0002-5237-0463), Costanzo A., Romanelli M., Zalaudek I., and Gallo R.

Abstract

na

Published
2020

28. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis.

Author

Fargnoli, M. C., Esposito, M., Ferrucci, S., Girolomoni, G., Offidani, A., Patrizi, A., Peris, K., Costanzo, A., Malara, G., Pellacani, G., Romanelli, M., Amerio, P., Cristaudo, A., Flori, M. L., Motolese, A., Betto, P., Patruno, C., Pigatto, P., Peccianti, C., and Stinco, G.

Subjects
DUPILUMAB, ATOPIC dermatitis, ADULTS, INFORMED consent (Medical law), MOLLUSCUM contagiosum
Abstract

G. Pellacani has been principal investigator in clinical trials sponsored by and/or received personal fees from AbbVie, Almirall, Eli-Lilly, Leo Pharma, Novartis, and Sanofi. S.P. Cannavò has been principal investigator in clinical trials sponsored by and/or received personal fees from AbbVie, Celgene, Eli-Lilly, Janssen-Cilag, Leo Pharma, Novartis, Sanofi. L. Stingeni has been principal investigator in clinical trials sponsored by and/or received personal fees from AbbVie, Almirall, Celgene, Eli-Lilly, Janssen, Novartis, and Sanofi-Genzyme. [Extracted from the article]

Published
2022
Full Text
View/download PDF

29. Effectiveness of cyclosporine A in patients with moderate to severe plaque psoriasis in a real-life clinical setting in Italy: the TRANSITION study.

Author

Marsili, F., Travaglini, M., Stinco, G., Manzoni, R., Tiberio, R., Prignano, F., Mazzotta, A., Cannavò, S. P., Cuccia, A., Germino, M., Bongiorno, M. R., Persechino, S., Florio, T., Pettinato, M., Tabanelli, M., Sarkar, R., Aloisi, E., Bartezaghi, M., and Orsenigo, R.

Subjects
CYCLOSPORINE, PSORIASIS, PSORIATIC arthritis, TREATMENT effectiveness
Abstract

Cyclosporine A (CsA) is one of the systemic therapeutic options for moderate-to-severe psoriasis, based on its efficacy and rapidity of action. The current study investigated the response to CsA in patients with moderate-to-severe plaque psoriasis. TRANSITION was an observational, cross-sectional, multicentre study which evaluated the proportion of partial- and suboptimal-responders among patients with moderate-to-severe plaque psoriasis treated with continuous CsA for ≥12 weeks. Patients demonstrating a Psoriasis Area and Severity Index (PASI) response of ≥90, ≥75 and <90, ≥50 and <75 and <50 were defined as responders, suboptimal-responders, partial-responders, and non-responders, respectively. A total of 196 patients (mean age, 46.6 years; 62.8% males) from 14 sites in Italy were evaluated. At the study visit, the mean (SD) PASI score was 4.2(5.5) compared with 15.3(7.1) prior to the last CsA cycle. For response categories, 39.8%, 22.4%, 16.8%, and 20.9% of patients were responders, suboptimal-responders, partial-responders, and non-responders to CsA treatment. Overall, 28.6% of patients permanently discontinued treatment with CsA (lack of efficacy [10.2%], poor tolerability and voluntary discontinuation [3.6% each], and other [11.7%]). Patients were only partially satisfied with CsA treatment, reporting measurable impact on quality of life. Only 40% patients showed a satisfactory response to CsA. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

33. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis

Author

Fargnoli, M. C., primary, Esposito, M., additional, Ferrucci, S., additional, Girolomoni, G., additional, Offidani, A., additional, Patrizi, A., additional, Peris, K., additional, Costanzo, A., additional, Malara, G., additional, Pellacani, G., additional, Romanelli, M., additional, Amerio, P., additional, Cristaudo, A., additional, Flori, M. L., additional, Motolese, A., additional, Betto, P., additional, Patruno, C., additional, Pigatto, P., additional, Peccianti, C., additional, Stinco, G., additional, Zalaudek, I., additional, Bianchi, L., additional, Boccaletti, V., additional, Cannavo, S. P., additional, Cusano, F., additional, Lembo, S., additional, Mozzillo, R., additional, Gallo, R., additional, Potenza, C., additional, Rongioletti, F., additional, Tiberio, R., additional, Grieco, T., additional, Micali, G., additional, Persechino, S., additional, Pettinato, M., additional, Pucci, S., additional, Stingeni, L., additional, Caruso, C., additional, and Argenziano, G., additional

Published
2020
Full Text
View/download PDF

34. Effectiveness of cyclosporine A in patients with moderate to severe plaque psoriasis in a real-life clinical setting in Italy: the TRANSITION study

Author

Marsili, F., primary, Travaglini, M., additional, Stinco, G., additional, Manzoni, R., additional, Tiberio, R., additional, Prignano, F., additional, Mazzotta, A., additional, Cannavò, S. P., additional, Cuccia, A., additional, Germino, M., additional, Bongiorno, M. R., additional, Persechino, S., additional, Florio, T., additional, Pettinato, M., additional, Tabanelli, M., additional, Sarkar, R., additional, Aloisi, E., additional, Bartezaghi, M., additional, and Orsenigo, R., additional

Published
2020
Full Text
View/download PDF

35. 定义在非癌症皮肤疾病的皮肤镜检查研究中应使用的术语和参数

Author

Errichetti, E., primary, Zalaudek, I., additional, Kittler, H., additional, Apalla, Z., additional, Argenziano, G., additional, Bakos, R., additional, Blum, A., additional, Braun, R., additional, Ioannides, D., additional, Lacarrubba, F., additional, Lazaridou, E., additional, Longo, C., additional, Micali, G., additional, Moscarella, E., additional, Paoli, J., additional, Papageorgiou, C., additional, Russo, T., additional, Scope, A., additional, Stinco, G., additional, Thomas, L., additional, Toncic, R.J., additional, Tschandl, P., additional, Cabo, H., additional, Hallpern, A., additional, Hofmann‐Wellenhof, R., additional, Malvehy, J., additional, Marghoob, A., additional, Menzies, S., additional, Pellacani, G., additional, Puig, S., additional, Rabinovitz, H., additional, Rudnicka, L., additional, Vakirlis, E., additional, Soyer, P., additional, Stolz, W., additional, Tanaka, M., additional, and Lallas, A., additional

Published
2020
Full Text
View/download PDF

36. Defining the terminology and parameters that should be used in studies into dermoscopy for non‐cancer skin diseases

Author

Errichetti, E., primary, Zalaudek, I., additional, Kittler, H., additional, Apalla, Z., additional, Argenziano, G., additional, Bakos, R., additional, Blum, A., additional, Braun, R., additional, Ioannides, D., additional, Lacarrubba, F., additional, Lazaridou, E., additional, Longo, C., additional, Micali, G., additional, Moscarella, E., additional, Paoli, J., additional, Papageorgiou, C., additional, Russo, T., additional, Scope, A., additional, Stinco, G., additional, Thomas, L., additional, Toncic, R.J., additional, Tschandl, P., additional, Cabo, H., additional, Hallpern, A., additional, Hofmann‐Wellenhof, R., additional, Malvehy, J., additional, Marghoob, A., additional, Menzies, S., additional, Pellacani, G., additional, Puig, S., additional, Rabinovitz, H., additional, Rudnicka, L., additional, Vakirlis, E., additional, Soyer, P., additional, Stolz, W., additional, Tanaka, M., additional, and Lallas, A., additional

Published
2020
Full Text
View/download PDF

39. Adamantiades-Behçet Disease at the Beginning of the Silk Route: North-East Italian Experience

Author

Bergamo, S., di Meo, N., Stinco, G., Bonin, S., Trevisini, S., Trevisan, G., Bergamo, S., di Meo, N., Stinco, G., Bonin, S., Trevisini, S., and Trevisan, G.

Subjects
Adult, Male, Letter, recurrent disease, Sensitivity and Specificity, Adamantiades Behcet disease, adult, Behcet disease, case control study, clinical protocol, controlled study, dermatologist, diagnostic test accuracy study, female, human, Italy, lichen planus, lupus erythematosus, major clinical study, male, medical examination, mouth disease, mucous membrane pemphigoid, population based case control study, practice guideline, receiver operating characteristic, sensitivity and specificity, ymptom, Adamantiades-Behçet's disease, Recurrent oral aphtosis, Silk Route, Humans, lupus erythematosu, lichen planu, Behcet Syndrome, Middle Aged, Case-Control Studies, Female
Abstract

Dear Editor, Adamantiades-Behçet's disease (ABD) is an inflammatory disease classified as vasculitis, which was originally diagnosed in patients with aphthous stomatitis, genital ulcerations, and ocular manifestations. However, any organ or system may be involved, particularly the central and peripheral nervous systems, joints, as well as the gastrointestinal tract. The etiology of ABD is still not fully understood, but some evidence indicates that an autoimmune process could be triggered by an infectious or environmental agent specific for the geographic region (1). Although BD can occur worldwide, it is most prevalent in the region along the ancient commercial route called the "Silk Road". In Italy, studies on the precise prevalence of ABD are lacking (2). As there are no specific diagnostic laboratory tests or histopathologic findings which confirm the preliminary diagnosis, the final diagnosis should be based on clinical criteria (3). Skin and mucosae are the target organs of this disease, and therefore their involvement has been considered in the numerous diagnostic criteria developed over the years (4). The first most important and popular criteria were created in 1990 by the International Study Group (ISG) (5). Because of their low sensitivity, the new International Criteria for Behçet's Disease (ICBD) were established, and were presented at the International Conference of Behçet's Disease in Lisbon in 2006 (6,7). In 2014, the International Team for the Revision of the International Criteria for BD submitted new criteria assigning 2 points to ocular lesions, oral aphthosis, and genital aphthosis, and 1 point to skin lesions, central nervous system involvement, and vascular manifestations. The pathergy test, when used, was assigned 1 point. A patient scoring ≥4 points is classified as having BD (8). We performed a single center, case-control study on a cohort of patients of Friuli Venezia Giulia, enrolled from January 2010 to September 2015 in the Dermatology Unit of the University of Trieste. The aim was to analyze the clinical features and compare the sensitivity, specificity, and accuracy of the three diagnostic criteria for ABD presented above in patients born in this particular region which is located at the very start of the "Silk Route". We enrolled 153 consecutive patients (74 cases and 79 controls) in the study. The characteristics and clinical features of patients and controls are summarized in Table 1. The most common diagnoses in the control group were recurrent oral aphtosis, lichen planus, mucous-membrane pemphigoid, and lupus erythematosus. The inclusion criterion was the presence of at least one principal clinical feature of ABD (oral aphtosis, genital aphtosis, skin lesions, ocular involvement) properly recorded in clinical records. Patient recruitment was done in a consecutive manner. Exclusion criteria were incomplete clinical records and absence of follow-up data. The diagnosis of ABD was established by expert dermatologists, without the use of any particular diagnostic criterion. For ABD, diagnosis agreement among dermatologists was required. The study was conducted according to the Declaration of Helsinki protocols. Possible associations between categorical variables were detected by the use of Fisher's exact test or Pearson χ2 test, depending on the sample size. Logistic regression was performed in order to identify which symptoms are of higher impact in the diagnosis of ABD. A comparison in terms of sensitivity, specificity, and accuracy among the three diagnostic criteria (ISG 1990, ITR 2006, and ITR 2014) was performed. The receiver operator characteristic (ROC) curve was obtained for each diagnostic criterion. Data were produced with a 95% confidence interval; P values0.05 were considered statistically significant. Statistical analysis was done using Stata SE12 software (Stata Corporation, Tx, USA). According to our data, patients with ABD had a significantly lower age at diagnosis compared with controls (P=0.0001); this was confirmed for both men (P=0.0006) and women (P=0.004). The presence of oral aphtosis was not necessarily pathognomonic of ABD (P=0.005) as it was found in 97.3% of patients with ABD and in 83.5% of controls. Genital aphtosis was directly associated with ABD diagnosis (P0.001), as it was present in 79.7% of patients with ABD, but in only 8.9% of controls. Furthermore, even skin manifestations and ocular lesions were observed at different rates in patients with ABD and controls (P0.001 and P=0.003, respectively). The presence of pseudofolliculitis was significantly more frequent in patients than in controls (P0.001), whereas erythema nodosum and skin aphtosis did not differ considerably between ABD and controls. Joint manifestations were as common in patients with ABD as in controls (P=0.6): arthralgia and arthritis alone do not indicate a diagnosis of ABD. Neurological symptoms as well as vascular involvement, if present, can be suggestive of ABD, but their absence does not exclude an ABD diagnosis (P=0.06 and P=0.04). Positive pathergy tests and positive HLA B51 tests were significantly more frequent in patients than in controls (P=0.007 and P=0.009, respectively), although if negative they did not exclude a diagnosis of ABD. Logistic regression showed that genital aphtosis (odds ratio (OR)=12948, P0.001), neurological manifestations (OR=819.263, P=0.001), vascular manifestations (OR=240.2573, P=0.001), cutaneous manifestations (OR=104.5625, P=0.002), oral aphtosis (OR=145.3229, P=0.004), and younger age at diagnosis (OR=0.8950334, P=0.000) were associated with ABD diagnosis (Table 2). There was no single pathognomonic symptom of ABD. We found that the ITR criteria -both from 2006 and 2014 - had a higher sensitivity (98.7% and 100%, respectively), specificity (94.9% and 97.9%, respectively), and accuracy (96.7% and 98.7%, respectively) compared with the ISG 1990 criterion, which scored 66% sensitivity, 100% specificity, and 83.7% accuracy. Area Under Roc Curve (AUC) was significantly different between ISG 1990 and ITR 2006 and between ISG 1990 and ITR 2014 (Figure 1). Even though no statistically significant difference was found between the ITR 2014 and ITR 2006 criteria, the former had a better performance according to our records. The clinical features reported in our retrospective case-control study are comparable to data found in the literature from European and international reports. A recent study (8) found a similar organ involvement percentage to our study, although we found a higher prevalence of HLA B51 positive patients and a lower percentage of ocular manifestations in our records. The results of the logistic regression performed based on our records indicate genital aphtosis, oral aphtosis, ocular involvement, neurological signs, and vascular features are more strongly linked to the diagnosis of ABD. According to our data, the presence of oral aphtosis is not paramount for the diagnosis of ABD, which fits well with the intent of the ITR 2006 and 2014 diagnostic criteria. The new ITR 2014 criteria added neurological signs to the diagnostic symptoms of ABD, emphasizing the importance of a multidisciplinary approach to patients suspected to have ABD.

Published
2018

40. Atlas of Pediatric Dermatoscopy

Author

Micali G, Lacarrubba F, Stinco G, Argenziano G, Neri I., Micali, G, Lacarrubba, F, Stinco, G, Argenziano, G, and Neri, I.

Published
2018

45. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: results from extension phase of the SUPREME study

Author

Papini, M., Cusano, F., Romanelli, Margherita, Burlando, M., Stinco, G., Girolomoni, G., Peris, Ketty, Potenza, C., Offidani, A., Bartezaghi, M., Aloisi, E., Costanzo, Rosa Maria Alba, Bianchi, L., Bottoni, U., Buligan, C., Brazzelli, V., Campanati, A., Cantoresi, F., Capo, A., Cattaneo, A., Dapavo, P., Giglio, M., Lernia, V., Nuzzo, S., Simone, Carmen, Dusi, D., Fargnoli, Maria Concetta, Flori, L., Franchi, C., Galluzzo, M., Ghilardi, A., Hansel, K., Loconsole, F., Lora, V., Malagoli, P., Malara, G., Mastrandrea, V., Megna, M., Mercuri, R., Musumeci, L., Naldi, L., Narcisi, A., Orsini, Diego, Pagnanelli, G., Patrizi, A., Pau, M., Pellacani, G., Persechino, S., Piaserico, S., Pietroleonardo, L., Prignano, F., Reseghetti, A., Russo, F., Sirna, R., Skroza, N., Stingeni, L., Trevisini, S., Zane, C., Zichichi, L., Zini, A., Romanelli M., Peris K. (ORCID:0000-0002-5237-0463), Costanzo A., Simone C., Fargnoli C., Orsini D., Papini, M., Cusano, F., Romanelli, Margherita, Burlando, M., Stinco, G., Girolomoni, G., Peris, Ketty, Potenza, C., Offidani, A., Bartezaghi, M., Aloisi, E., Costanzo, Rosa Maria Alba, Bianchi, L., Bottoni, U., Buligan, C., Brazzelli, V., Campanati, A., Cantoresi, F., Capo, A., Cattaneo, A., Dapavo, P., Giglio, M., Lernia, V., Nuzzo, S., Simone, Carmen, Dusi, D., Fargnoli, Maria Concetta, Flori, L., Franchi, C., Galluzzo, M., Ghilardi, A., Hansel, K., Loconsole, F., Lora, V., Malagoli, P., Malara, G., Mastrandrea, V., Megna, M., Mercuri, R., Musumeci, L., Naldi, L., Narcisi, A., Orsini, Diego, Pagnanelli, G., Patrizi, A., Pau, M., Pellacani, G., Persechino, S., Piaserico, S., Pietroleonardo, L., Prignano, F., Reseghetti, A., Russo, F., Sirna, R., Skroza, N., Stingeni, L., Trevisini, S., Zane, C., Zichichi, L., Zini, A., Romanelli M., Peris K. (ORCID:0000-0002-5237-0463), Costanzo A., Simone C., Fargnoli C., and Orsini D.

Abstract

na

Published
2019

46. Ultrasonographic detection of subclinical enthesitis and synovitis: a possible stratification of psoriatic patients without clinical musculoskeletal involvement

Author

Zuliani, F, Zabotti, A, Errichetti, E, Tinazzi, I, Zanetti, A, Carrara, G, Quartuccio, L, Sacco, S, Giovannini, I, Stinco, G, De Vita, S, Zuliani, F, Zabotti, A, Errichetti, E, Tinazzi, I, Zanetti, A, Carrara, G, Quartuccio, L, Sacco, S, Giovannini, I, Stinco, G, and De Vita, S

Abstract

ObjectiveTo evaluate the prevalence of articular/extra-articular inflammatory lesions and structural damage on ultrasonography in patients suffering from psoriasis as well as to assess possible correlations between ultrasonographic elementary lesions and clinical features.MethodsPsoriatic patients without musculoskeletal symptoms and healthy controls (HCs) were recruited. All patients received a blinded extended ultrasonographic examination of 42 joints, 12 entheses and 32 tendons. Active synovitis was defined by the presence of a grade >= 2 for grey scale (GS) and >= 1 for power Doppler (PD), while active enthesitis corresponded to entheseal hypoecogenicity in GS and entheseal PD signal (<2 mm from bone insertion).ResultsForty psoriatic patients and 20 HCs were included. A total of 2516 joints and 712 entheses were scanned. Active synovitis was found in 11/40 (27.5%) psoriatic patients and 0/20 HCs (p=0.01). Articular synovitis (GS=2) was more frequent in psoriasis than in HCs [ 34/40 (85.0%) and 11/20 (55.0%) respectively; p=0.024). Active enthesitis was found only in psoriatic patients, with a prevalence of 20.0% (8/40) (p=0.04). No significant difference in the prevalence of tenosynovitis or paratenonitis was observed between psoriatic patients and HCs. In psoriasis cohort, age was correlated with the presence of active synovitis (p=0.03), while male sex and a higher PASI score were independently correlated with the presence of active enthesitis (p=0.05 and p=0.034, respectively).ConclusionActive enthesitis and synovitis could be useful to identify subclinical psoriatic arthritis. This might represent a relevant clinical step to better stratify patients with psoriasis.

Published
2019

47. Improving the disease awareness: how a communication campaign brings hidradenitis suppurativa to the light

Author

Ribero, S., Dapavo, P., Casalegno, C., Alaibac, M., Argenziano, G., Arpaia, N. G., Bagnoni, G., Berti, Emanuele, Bianchi, L., Bianchini, D., Calzavara Pinton, P., Cannavo, S. P., Congedo, Maria Teresa, Corrao, S., Costanzo, Rosa Maria Alba, Cusano, F., Dattola, S., Dattoli, S., Deledda, S., Donini, M., Fabbrocini, G., Teresa Fierro, M., Foti, C., Galluccio, A. G., Gatti, A., Rene Girardelli, C., Girolomoni, G., Lemme, G., Malagoli, P., Malara, G., Mercuri, S. R., Micali, G., Montesu, M. A., Offidani, A., Papini, M., Parodi, A., Patrizi, A., Pellacani, G., Peris, Ketty, Piccirillo, A., Pigatto, P., Pimpinelli, N., Potenza, C., Provenzano, Katia Elisabetta, Romanelli, Margherita, Rongioletti, F., Savoia, P., Simonacci, Matteo, Sirna, R., Stinco, G., Valenti, Gianfranco, Zalaudek, Iris, Berti E., Congedo M., Costanzo A., Peris K. (ORCID:0000-0002-5237-0463), Provenzano E., Romanelli M., Simonacci M., Valenti G., Zalaudek I., Ribero, S., Dapavo, P., Casalegno, C., Alaibac, M., Argenziano, G., Arpaia, N. G., Bagnoni, G., Berti, Emanuele, Bianchi, L., Bianchini, D., Calzavara Pinton, P., Cannavo, S. P., Congedo, Maria Teresa, Corrao, S., Costanzo, Rosa Maria Alba, Cusano, F., Dattola, S., Dattoli, S., Deledda, S., Donini, M., Fabbrocini, G., Teresa Fierro, M., Foti, C., Galluccio, A. G., Gatti, A., Rene Girardelli, C., Girolomoni, G., Lemme, G., Malagoli, P., Malara, G., Mercuri, S. R., Micali, G., Montesu, M. A., Offidani, A., Papini, M., Parodi, A., Patrizi, A., Pellacani, G., Peris, Ketty, Piccirillo, A., Pigatto, P., Pimpinelli, N., Potenza, C., Provenzano, Katia Elisabetta, Romanelli, Margherita, Rongioletti, F., Savoia, P., Simonacci, Matteo, Sirna, R., Stinco, G., Valenti, Gianfranco, Zalaudek, Iris, Berti E., Congedo M., Costanzo A., Peris K. (ORCID:0000-0002-5237-0463), Provenzano E., Romanelli M., Simonacci M., Valenti G., and Zalaudek I.

Abstract

Background: Hidradenitis suppurativa is an inflammatory skin disease that presents a recurrence of painful and suppurating lesions in the apocrine gland-bearing regions, with a strong impact on the patients’ life quality. Despite its peculiar presentation, early forms are often underestimated by patients and this would inevitably result in late diagnosis and delayed therapy. Objectives: Improved communication around the disease could facilitate self-diagnosis and a quicker response from healthcare practitioners, especially in this moment when we dispose of effective treatment against this disease. Methods: A HS awareness campaign was conducted for 2 years with the help of a media agency and a patients’ association. Results: Results confirm that a better communication has a strong impact on the disease awareness. Conclusions: This paper demonstrates that the more this disease awareness is carried on, the more quick, effective and efficient the patient's management could be.

Published
2019

49. Borreliosi di Lyme

Author

Trevisan G., Nan K., Bonin S., Stinco G., Trevisan, G., Nan, K., Bonin, S., and Stinco, G.

Subjects
Borreliosi di Lyme, Borrelia burgdorferi sensu lato, Ixodes, zoonosi, Ixode
Abstract

La borreliosi di Lyme (BL) è una zoonosi che causa una infezione multisistemica, convenzionalmente suddivisa in stadi clinici, che interessa numerosi organi e in particolare la cute, le articolazioni, il sistema nervoso, gli occhi e il cuore. È causata da una spirocheta mobile a lenta crescita del genere Borrelia, nota come Borrelia burgdorferi (Bb) sensu lato e trasmessa all’uomo dal morso di una zecca dura del genere Ixodes.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results